WATERTOWN, Mass.–(BUSINESS WIRE)–Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics firm centered on the event and commercialization of novel built-in drug and supply options for the localized therapy of sufferers with ear, nostril and throat ailments, right now introduced that Maria Palasis, Ph.D., Lyra’s President and Chief Govt Officer, will current on the Bank of America Merrill Lynch Digital International Healthcare Convention on Thursday, Might 14, 2020 at 3:00 p.m. ET.
events can entry the stay audio webcast for this convention from the Investor Relations part of the corporate’s web site at www.lyratherapeutics.com. The webcast replay will likely be out there after the conclusion of the stay presentation for roughly 30 days.
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage therapeutics firm centered on the event and commercialization of novel built-in drug and supply options for the localized therapy of sufferers with ear, nostril and throat ailments. The corporate’s proprietary know-how platform, XTreo™, is designed to exactly and constantly ship medicines on to the affected tissue for sustained intervals with a single administration. The corporate’s preliminary product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a short, non-invasive, in-office process and meant to ship as much as six months of steady drug remedy to the sinonasal passages for the therapy of persistent rhinosinusitis, or CRS. The therapeutic embedded inside LYR-210 and LYR-220 is mometasone furoate, which is the energetic ingredient in varied FDA-approved medicine and has a well-established efficacy and security profile. CRS is an inflammatory illness of the paranasal sinuses which ends up in debilitating signs and important morbidities and impacts roughly 14 million individuals in the USA. The corporate is advancing LYR-210 as a possible most popular different to surgical procedure in an ongoing Part 2 medical trial for CRS sufferers who’ve failed medical administration. In its Part 1 medical trial, LYR-210 met its major security endpoint, and it was noticed that sufferers typically skilled important and fast, clinically significant and sturdy enchancment in SNOT-22 scores, a longtime affected person symptom severity scale, by means of week 25, which was the tip of the trial. The corporate can also be creating LYR-220 to be used in CRS sufferers who’ve an enlarged nasal cavity resulting from sinus surgical procedure however proceed to require therapy to handle CRS signs. Past CRS, the corporate believes its XTreo platform has potential purposes in different illness areas, which it’s actively exploring to additional broaden the platform’s therapeutic potential.
For extra info, please go to www.lyratherapeutics.com and comply with us on LinkedIn.
This press launch comprises forward-looking statements throughout the that means of the Personal Securities Litigation Reform Act of 1995. All statements contained on this press launch that don’t relate to issues of historic truth must be thought of forward-looking statements, together with statements concerning upcoming shows, the corporate’s product candidates and the corporate’s XTreo platform. These statements are neither guarantees nor ensures, however contain identified and unknown dangers, uncertainties and different vital components which will trigger the corporate’s precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements, together with, however not restricted to, the next: the truth that the corporate has incurred important losses since inception and anticipate to incur losses for the foreseeable future; the corporate’s want for added funding, which is probably not out there; the corporate’s restricted working historical past; the truth that the corporate has no accepted merchandise; the truth that the corporate’s product candidates are in varied phases of improvement; the truth that the corporate is probably not profitable in its efforts to determine and efficiently commercialize its product candidates; the truth that medical trials required for the corporate’s product candidates are costly and time-consuming, and their consequence is unsure; the truth that the FDA could not conclude that sure of the corporate’s product candidates fulfill the necessities for the Part 505(b)(2) regulatory approval pathway; the corporate’s lack of ability to acquire required regulatory approvals; results of not too long ago enacted and future laws; the opportunity of system failures or safety breaches; results of serious competitors; the truth that the profitable commercialization of the corporate’s product candidates will rely partially on the extent to which governmental authorities and well being insurers set up protection, enough reimbursement ranges and pricing insurance policies; failure to attain market acceptance; product legal responsibility lawsuits; the truth that the corporate depends on third events for the manufacture of supplies for its analysis packages, pre-clinical research and medical trials; the corporate’s reliance on third events to conduct its preclinical research and medical trials; the corporate’s lack of ability to achieve establishing and sustaining collaborative relationships; the corporate’s reliance on sure suppliers essential to its manufacturing; failure to acquire and preserve or adequately defend the corporate’s mental property rights; failure to retain key personnel or to recruit certified personnel; difficulties in managing the corporate’s progress; results of pure disasters; the truth that the worldwide pandemic brought on by COVID-19 might adversely affect the corporate’s enterprise and operations, together with the corporate’s medical trials; the truth that the price of the corporate’s frequent stock could also be unstable and fluctuate considerably; important prices and required administration time because of working as a public firm and any securities class motion litigation. These and different vital components mentioned below the caption “Risk Factors” within the firm’s prospectus filed in reference to its preliminary public providing and its different filings with the SEC might trigger precise outcomes to vary materially from these indicated by the forward-looking statements made on this press launch. Any such forward-looking statements signify administration’s estimates as of the date of this press launch. Whereas the corporate could elect to replace such forward-looking statements in some unspecified time in the future sooner or later, it disclaims any obligation to take action, even when subsequent occasions trigger its views to vary.